Early observations and pilot data that first suggested a new direction
GLP-1 receptor agonists were initially developed for glycemic control in type 2 diabetes. Early cardiovascular outcome trials were mandated by the FDA to confirm safety, but the LEADER trial provided the first strong signal that liraglutide conferred genuine cardiovascular benefit. Among 9,340 patients with type 2 diabetes and high cardiovascular risk, liraglutide reduced the composite of cardiovascular death, nonfatal MI, or nonfatal stroke by 13% over 3.8 years. This finding transformed the drug class from glucose-lowering agents into potential cardiovascular therapies.
Landmark RCTs and pivotal trials that established the evidence base
SUSTAIN-6 confirmed the cardiovascular signal with subcutaneous semaglutide, demonstrating a 26% reduction in MACE among 3,297 patients with type 2 diabetes over 104 weeks. The STEP 1 trial then expanded the paradigm beyond diabetes entirely, showing that semaglutide 2.4 mg produced 14.9% weight loss in 1,961 adults with obesity but without diabetes. These trials collectively established that GLP-1 receptor agonists exerted effects well beyond glycemic control.
Follow-up studies, subgroup analyses, and real-world validation
The SELECT trial definitively extended the cardiovascular benefit to patients with obesity but without diabetes. Among 17,604 participants with established CVD, semaglutide 2.4 mg reduced MACE by 20% over a mean follow-up of 39.8 months. The FLOW trial then demonstrated a 24% reduction in major kidney disease events among 3,533 patients with type 2 diabetes and CKD, confirming that the benefits of GLP-1 receptor agonists extended to renal protection. Both trials were stopped early for efficacy.
Integration into clinical practice guidelines and recommendations
Major guidelines incorporated GLP-1 receptor agonists as first-line therapy for patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, independent of glycemic control. The ADA/EASD consensus and the 2023 ESC guidelines both elevated GLP-1 RAs to foundational cardiorenal protective therapy. The FDA approved semaglutide for cardiovascular risk reduction in obesity regardless of diabetes status following SELECT.
ADA/EASD
GLP-1 RA recommended as first-line injectable for patients with T2D and established ASCVD or high cardiovascular risk
ESC
GLP-1 RA recommended (Class I) for cardiovascular risk reduction in T2D with or at high risk of ASCVD
Now
Current standard of care and ongoing research directions
GLP-1 receptor agonists are now recognized as multi-organ protective agents spanning cardiovascular, renal, and metabolic domains. The evidence base has expanded from glycemic endpoints to hard cardiovascular and kidney outcomes in patients with and without diabetes. Ongoing trials are evaluating these agents in heart failure with preserved ejection fraction, MASLD, and Alzheimer disease. The class represents one of the most significant therapeutic expansions in modern medicine.
Do GLP-1 receptor agonists provide cardiovascular benefit in patients without diabetes?+
The SELECT trial demonstrated that semaglutide 2.4 mg reduced MACE by 20% in 17,604 patients with obesity and established CVD but without diabetes (HR 0.80; 95% CI 0.72-0.90; p<0.001), confirming cardiovascular benefit independent of glycemic control.
What kidney benefits have been demonstrated with GLP-1 receptor agonists?+
The FLOW trial showed semaglutide reduced major kidney disease events by 24% (HR 0.76; 95% CI 0.66-0.88) in patients with T2D and CKD, including a 21% reduction in kidney-specific outcomes and a 29% reduction in cardiovascular death. The trial was stopped early for efficacy.
How much weight loss can be expected with semaglutide for obesity?+
In the STEP 1 trial, semaglutide 2.4 mg produced a mean weight loss of 14.9% at 68 weeks compared with 2.4% with placebo in adults with obesity without diabetes. Of those receiving semaglutide, 86.4% achieved at least 5% weight loss.
